The Generalized Myasthenia Gravis (GMG) Management Market is set for significant growth between 2025 and 2035, fueled by the rising prevalence of autoimmune diseases and advances in diagnostic technologies. As a chronic neuromuscular disorder, GMG requires complex treatment approaches, including corticosteroids, muscle relaxants, cholinesterase inhibitors, and monoclonal antibodies....